Menopause symptoms should not set the pace.
Prescription estradiol gel delivers systemic estrogen through the skin in an adjustable daily format.
About 10 minutes. No charge unless your clinician approves.
The adjustable route through menopause.
Perimenopause and menopause can make a familiar body feel suddenly unpredictable. Hot flashes interrupt meetings. Night sweats break sleep into pieces. Mood and the rhythm of the month stop following rules that worked for decades.
Estradiol is one of the central hormones changing underneath that transition.
This gel delivers bioidentical 17-beta estradiol through the skin and into circulation without a first pass through the liver. The format matters because it gives your clinician room to work in small, deliberate increments rather than forcing every adjustment into a fixed-strength jump.
You apply a measured dose to clean, dry skin once a day. The gel dries in minutes. From there, the plan is allowed to be what menopause rarely is: adjustable. Your provider follows symptoms and response, then decides whether the dose should move, hold, or whether another format makes more sense.
Gel earns its place because the format does real work: daily transdermal delivery, adjustable dosing, and no patch to wear. The route is a practical and clinical decision, not a footnote after a generic hormone discussion.
Read the evidence →For the years when your body stopped following the old rules.
Menopause Is Interrupting the Day
Hot flashes, night sweats, and broken sleep are no longer background annoyances. They are affecting how you work, rest, and move through the week. Estrogen therapy is the most effective treatment medicine has for moderate to severe vasomotor symptoms, and your clinician determines whether it is appropriate for you.
Perimenopause Arrived Before You Expected It
Periods still happen, but the rest of the system has become less predictable. Sleep fractures, mood shifts, and cycles change. This is exactly the stage where a generic answer is least useful and a real hormone-therapy conversation matters most.
You Want Room to Fine-Tune
You are not looking for a treatment plan that gets set once and ignored. Gel dosing can move in small increments, giving your clinician a format that can be adjusted as your response becomes clear.
Whether the gel suits your symptoms and your history is determined by a licensed provider from your Assessment. Compounded by a licensed 503A pharmacy and not an FDA-approved drug product.
This might not be the right fit if:
- History of breast cancer or another estrogen-dependent malignancy
- Unexplained vaginal bleeding
- History of blood clots, stroke, or heart attack
- Active liver disease
- Pregnancy or planned pregnancy
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Estradiol Gel, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- Bioidentical 17-beta estradiol delivered through the skin
- One measured application daily to clean, dry skin
- Dose adjusted in small increments by your provider, guided by your response
- Paired with micronized progesterone when you have a uterus, per standard of care
- Ongoing provider review with treatment changes handled through your care team
Prescription issued subject to provider judgment. Results vary. Not a guarantee of outcomes.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Hormones & Vitality.
Estradiol Patches
Twice weekly. Steady by design.
Prescription estradiol patches provide steady transdermal delivery with a twice-weekly change schedule.
Estradiol Tablet
A familiar form, backed by serious hormone care.
Prescription oral estradiol puts established hormone therapy into a familiar, straightforward daily form.
Estradiol Vaginal Cream
Local treatment for an intimate problem.
Prescription vaginal estradiol delivers local treatment directly to the tissue at the center of the concern.
What the research shows
Specialist bodies still rate hormone therapy the most effective option for menopause symptoms.
The detail
The 2022 hormone therapy position statement of The North American Menopause Society concludes that hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause, and that for women under 60, or within 10 years of menopause onset and without contraindications, the benefit-risk ratio is favourable for treating those symptoms.1
All three doses beat placebo on hot flush frequency and severity.
The detail
In the 12-week randomized, double-blind, placebo-controlled registration trial of estradiol gel 0.1 percent, 488 postmenopausal women were evaluated across three once-daily doses of 1.0, 0.5 and 0.25 mg of estradiol, with estimated daily deliveries of 0.027, 0.009 and 0.003 mg, and placebo. All three doses produced statistically significant reductions in the frequency and severity of moderate to severe vasomotor symptoms compared with placebo, maintained through treatment, and all three also improved the objective signs of vulvar and vaginal atrophy, vaginal pH and the percentage of superficial cells.2 The FDA-approved labeling describes the same trial in 495 postmenopausal women aged 34 to 89, mean age 54.6, who recorded at least 50 moderate to severe hot flushes per week at baseline; separation from placebo came at week 4 for the two higher doses and week 7 for the lowest, and was statistically significant for all three at week 12.3
A second approved gel separated from placebo gel, by a modest margin.
The detail
A second approved estradiol gel, at 0.06 percent, was tested in a placebo-controlled trial of 145 postmenopausal women aged 29 to 67 randomized to 1.25 g of gel containing 0.75 mg of estradiol or to placebo gel for 12 weeks. At week 12 the mean number of moderate to severe hot flushes per day fell by 7.55 on the gel and by 5.84 on placebo, a difference of 1.71 flushes per day, p equals 0.043, with a wider separation on the daily severity score, p less than 0.001.4
Low-dose transdermal estradiol beat placebo in eight of nine trials.
The detail
A systematic review restricted to double-blind, placebo-controlled randomized trials of transdermal estrogen below the equivalent of 0.05 mg of 17-beta estradiol identified nine trials in postmenopausal women who had at least seven hot flashes a day or 50 a week. Mean daily reductions from baseline were 9.36, 7.91 and 7.07 hot flashes across three descending dose bands against 5.07 on placebo, and eight of the nine trials reported a significant difference from placebo at p less than 0.05.5
The two WHI trials did not find the same thing, and both found real risk.
The detail
The Women’s Health Initiative ran two separate randomized, double-blind, placebo-controlled trials, and they did not find the same thing. In 16,608 postmenopausal women aged 50 to 79 with a uterus given oral conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg, hazard ratios over a mean 5.2 years were 1.29 for coronary heart disease, 95 percent confidence interval 1.02 to 1.63, 1.26 for invasive breast cancer, 1.00 to 1.59, 1.41 for stroke, 1.07 to 1.85, and 2.13 for pulmonary embolism, 1.39 to 3.25, which is 7, 8, 8 and 8 excess events per 10,000 person-years, alongside 6 fewer colorectal cancers and 5 fewer hip fractures.6 In 10,739 women with a prior hysterectomy given conjugated equine estrogens alone for an average 6.8 years, stroke rose, hazard ratio 1.39, 1.10 to 1.77, or 12 extra strokes per 10,000 person-years; hip fracture fell, 0.61, 0.41 to 0.91; coronary heart disease was unchanged, 0.91, 0.75 to 1.12; and breast cancer was 0.77, 0.59 to 1.01.7
How long since menopause changed the heart result. Stroke risk did not move.
The detail
A prespecified secondary analysis of both Women’s Health Initiative trials found the coronary result varied with how long a woman had been postmenopausal. At less than 10 years since menopause the hazard ratio for coronary heart disease was 0.76, 95 percent confidence interval 0.50 to 1.16; at 10 to 19 years 1.10, 0.84 to 1.45; at 20 or more years 1.28, 1.03 to 1.58, p for trend 0.02, with absolute excess risks of minus 6, 4 and 17 events per 10,000 person-years. Stroke risk was elevated regardless of timing, hazard ratio 1.32, 1.12 to 1.56.8
What it does not show
No approved or established use for anti-aging, longevity, cognitive protection or cardiovascular prevention.
The detail
The approved uses are narrow. Estradiol gel labeling covers treatment of moderate to severe vasomotor symptoms due to menopause, and for one approved gel also moderate to severe symptoms of vulvar and vaginal atrophy. There is no approved or established use for anti-aging, longevity, cognitive protection or cardiovascular prevention, and the revised gel labeling states plainly that the safety and efficacy of the gel for the prevention of cardiovascular disorders has not been established.34
Placebo did a large share of the work, and every trial ran only 12 weeks.
The detail
Placebo did a large share of the work, and the trials were short. Hot flushes fell by 5.84 per day on placebo gel over 12 weeks in the 145-woman trial, and a Cochrane review of 24 double-blind randomized trials in 3,329 women found a substantial placebo response across the evidence base. The gel trials ran 12 weeks. They establish an effect while treatment continues, not that anything persists after it stops.49
The boxed warning changed in 2026.
The detail
That is a reassessment, not a disproof. The boxed warning changed in 2026, and that is a reassessment rather than a disproof. On November 10, 2025 the FDA asked manufacturers of menopausal hormone therapy to remove the cardiovascular disease, breast cancer and probable dementia language from the boxed warning while keeping the boxed warning about endometrial cancer for systemic estrogen-alone products, and the first revised labels were approved on February 12, 2026. In the revised gel labeling the Women’s Health Initiative stroke and venous thromboembolism findings remain under Warnings and Precautions and the WHI Memory Study probable dementia finding remains under Geriatric Use. The change is also not uniform: as of August 2026 some approved estradiol gel labels carry the endometrial-cancer-only boxed warning while others still carry the older four-part warning.341011
No trial cited here tested a compounded gel.
The detail
The trials do not transfer freely between products or routes. The Women’s Health Initiative tested oral conjugated equine estrogens, alone and with medroxyprogesterone acetate, not transdermal 17-beta estradiol, and the labeling states that the relevance of those findings to other doses, other routes of administration or other estrogen products is not known. The gel trials tested specific approved gel products at specified strengths for 12 weeks. No trial cited here tested a compounded gel.367
- The 2022 hormone therapy position statement of The North American… Menopause. 2022.PubMed
- Hedrick RE, Ackerman RT, Koltun WD, Halvorsen MB, Lambrecht LJ. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms… Menopause. 2009.
- FDA-approved prescribing information, DIVIGEL (estradiol gel) 0.1 percent, Vertical Pharmaceuticals LLC, label version 31 published February 2026.DailyMed
- FDA-approved prescribing information, ESTROGEL (estradiol gel) 0.06 percent, Ascend Therapeutics US LLC, label version 55 published May 2026.DailyMed
- Corbelli J, Shaikh N, Wessel C, Hess R. Low-dose transdermal estradiol for vasomotor symptoms: a systematic… Menopause. 2015.
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal… JAMA. 2002.
- Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with… JAMA. 2004.
- Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by… JAMA. 2007.
- MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus… Cochrane Database Syst Rev. 2004;(4):CD002978.
- US Food and Drug Administration. FDA requests labeling changes related to safety information to clarify… Drug safety statement, November 10, 2025.FDA
- US Food and Drug Administration. FDA approves labeling changes to menopausal hormone therapy products. Press announcement, February 12, 2026.FDA
Approved estradiol labeling carries a boxed warning that estrogen without a progestogen increases the risk of endometrial cancer in a woman who still has a uterus, so unopposed systemic estrogen is not an appropriate plan in that situation and progesterone belongs in the conversation.
Do not use if you have
- A history of breast cancer or another estrogen-dependent cancer
- Unexplained vaginal bleeding
- A prior blood clot, stroke or heart attack
- An inherited clotting disorder
- Liver disease
- A known anaphylactic reaction, angioedema, or hypersensitivity to the gel itself
- Pregnancy
Serious risks
- Stroke, deep vein thrombosis and pulmonary embolism
- Gallbladder disease
- Probable dementia in women who begin therapy at 65 or older
- Breast cancer when estrogen and a progestogen are taken together over longer use
Commonly reported
- Breast tenderness
- Irregular uterine bleeding
- Vaginal yeast infection
- Irritation where the gel is applied
Because it is a gel
- Estradiol can transfer to another person, or to a pet, through skin contact before the gel has dried
- Alcohol-based gels are flammable until dry, so the labeling directs you to keep the site away from flame and away from other people until it dries
Your provider weighs your age, your history, and how long you have been postmenopausal before prescribing, and revisits that judgment as your care continues. The serious risks are estrogen class risks.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
$99 per month, or $237 billed quarterly, which works out to $79 per month. The plan covers the clinical review, the prescription if you are approved, the medication, shipping, and ongoing provider oversight including dose adjustments and check-ins. There are no separate visit fees, and if your provider determines estradiol is not right for you, you pay nothing.
Systemic estrogen therapy carries real risks, including blood clots and stroke, and combined hormone therapy has been associated with an increased risk of breast cancer with longer use. Your individual risk depends on your age, health history, dose, route, and timing relative to menopause. Your provider walks through this with you plainly before anything is prescribed, and revisits it as your care continues.
If you have a uterus, taking systemic estrogen without a progestogen increases the risk of endometrial overgrowth and cancer. Pairing estrogen with micronized progesterone protects the uterine lining, and it is standard of care. If you have had a hysterectomy, your provider will typically prescribe estradiol on its own.